Liquid biopsies for multiple myeloma in a time of precision medicine
Open Access
- 4 April 2020
- journal article
- review article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 98 (4) , 513-525
Abstract
Multiple myeloma (MM) is a challenging, progressive, and highly heterogeneous hematological malignancy. MM is characterized by multifocal proliferation of neoplastic plasma cells in the bone marrow (BM) and sometimes in extramedullary organs. Despite the availability of novel drugs and the longer median overall survival, some patients survive more than 10 years while others die rapidly. This heterogeneity is mainly driven by biological characteristics of MM cells, including genetic abnormalities. Disease progressions are mainly due to the inability of drugs to overcome refractory disease and inevitable drug-resistant relapse. In clinical practice, a bone marrow biopsy, mostly performed in one site, is still used to access the genetics of MM. However, BM biopsy use is limited by its invasive nature and by often not accurately reflecting the mutational profile of MM. Recent insights into the genetic landscape of MM provide a valuable opportunity to implement precision medicine approaches aiming to enable better patient profiling and selection of targeted therapies. In this review, we explore the use of the emerging field of liquid biopsies in myeloma patients considering current unmet medical needs, such as assessing the dynamic mutational landscape of myeloma, early predictors of treatment response, and a less invasive response monitoring.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (FCT-PTDC/MEC-MHEM/30315/2017)
This publication has 123 references indexed in Scilit:
- Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myelomaBritish Journal of Cancer, 2012
- Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disordersBlood Cancer Journal, 2012
- EMT and Dissemination Precede Pancreatic Tumor FormationCell, 2012
- A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomasBritish Journal of Cancer, 2011
- Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cellsNature Communications, 2011
- Initial genome sequencing and analysis of multiple myelomaNature, 2011
- Cancer micrometastasesNature Reviews Clinical Oncology, 2009
- MicroRNAs regulate critical genes associated with multiple myeloma pathogenesisProceedings of the National Academy of Sciences, 2008
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences, 2008
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004